Keywords: Clinical trial; connective tissue disease; hypersensitivity pneumonitis; idiopathic pulmonary fibrosis; interstitial lung disease; lung transplantation; nintedanib; pirfenidone; sarcoidosis
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Epithelial ovarian cancer; Cervical cancer; Endometrial cancer; Bevacizumab; Molecular signatures; Pazopanib; Nintedanib; Trebanabib
Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability
Keywords: Nintedanib; Cyclodextrin; Intestinal permeability; p-Glycoprotein efflux; Pulmonary fibrosis;
Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice
Keywords: Prostate cancer; Nintedanib; Inflammation; TRAMP; IL-17; COX-2;
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Keywords: CI; confidence interval; DCR; disease control rate; DOC; docetaxel; EMA; European Medicines Agency; FDA; US Food and Drug Administration; HR; hazard ratio; ITT; intent to treat; NSCLC; non-small cell lung cancer; OR; odds ratio; ORR; objective response ra
Severe idiopathic pulmonary fibrosis: A clinical approach
Keywords: IPF; idiopathic pulmonary fibrosis; UIP; Usual Interstitial Pneumonia; FVC; Forced Vital Capacity; SVC; Slow Vital Capacity; FEV1; Forced Expiratory Volume in the first second; TLC; Total Lung Capacity; RV; Residual Volume; DLCO; Diffusing Capacity of the
Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Keywords: lung transplantation; idiopathic pulmonary fibrosis; anti-fibrotic therapy; pirfenidone; nintedanib; post-operative complications;
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Keywords: Nintedanib; Non-small cell lung cancer; Squamous;
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Keywords: AFAT; afatinib; ALK; anaplastic lymphoma kinase; CRIZ; crizotinib; CS; calibration standard; CV; coefficient of variation; DMSO; dimethylsulfoxide; EGFR; epidermal growth factor receptor; ERLO; erlotinib; IQC; internal quality control; IS; internal standa
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
Keywords: Covariates; Idiopathic pulmonary fibrosis; Nintedanib; Population pharmacokinetics;
Les nouveaux médicaments en pneumologie
Keywords: nintédanib; pneumologie; uméclidinium bromure; nintedanib; pneumology; umeclidinium bromide;
Experimental radiobiologyNintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator
Keywords: Nintedanib; Radiation-induced lung damage; Radiation pneumonitis; Radiation fibrosis; Small animal image-guided precision irradiation;
SEPAR's voiceGuidelines for the Medical Treatment of Idiopathic Pulmonary FibrosisNormativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática
Keywords: Idiopathic pulmonary fibrosis; Treatment; Pirfenidone; Nintedanib; Fibrosis pulmonar idiopática; Tratamiento; Pirfenidona; Nintedanib;
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group
Keywords: Non squamous NSCLC; Second line therapy; Nintedanib; Ramucirumab; Nivolumab; Pembrolizumab; Atezolizumab; Docetaxel; Therapeutic strategy;
Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence
Keywords: Idiopathic pulmonary fibrosis; Interstitial lung disease; Nintedanib; Pirfenidone;
The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis
Keywords: Idiopathic pulmonary fibrosis; Pirfenidone; Nintedanib; TOMORROW; INPULSIS; Diagnosis;
Simultaneous determination of nintedanib and its metabolite by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study
Keywords: Nintedanib; BIBF 1202; UPLC-MS/MS; Plasma; Pharmacokinetics;
A phase II study of nintedanib in patients with relapsed small cell lung cancer
Keywords: Nintedanib; SCLC; VEGFR;
Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
Keywords: Idiopathic pulmonary fibrosis (IPF); Pirfenidone; Nintedanib; IPF disease severity
Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment
Keywords: ANG-2; angiotensin-2; DMSO; dimethyl sulfoxide; EGF; epidermal growth factor; EGFR; epidermal growth factor receptor; FCS; fetal calf serum; FGF; fibroblast growth factor; HB-EGF; heparin-binding EGF-like growth factor; HGF; hepatocyte growth factor; ITGA
Two anti-angiogenic TKI-PET tracers, [11C]axitinib and [11C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents
Keywords: Axitinib; Nintedanib; TKI-Pet; Personalized medicine; VEGFR
Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC–MS/MS and its application in drug tissue distribution study
Keywords: Nintedanib; BIBF 1202; UPLC–MS/MS; Plasma; Pharmacokinetics; Tissue distribution
Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
Keywords: Clinical trials; Phase I; Docetaxel; Japanese; Nintedanib; Non-small-cell lung cancer; Pharmacokinetics;
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
Keywords: Pancreatic cancer; Nintedanib; Angiogenesis; Chemotherapy; Combination therapy
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
Keywords: Anti-angiogenesis; Docetaxel; Nintedanib; Non-small cell lung cancer; Quality of life;
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
Keywords: Clinical trials; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Therapy; Treatment; AE; acute exacerbation; AEC; alveolar epithelial cell; ANCOVA; analysis of covariance; DLCO; diffusing capacity of the lung for carbon monoxide; DPLD; diffuse par
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-Mechanistics, review of phase III randomized clinical trials, and regulatory implications
Keywords: Angiogenesis; Bevacizumab; Pazopanib; Cediranib; Trebananib; Nintedanib;
What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Keywords: Nintedanib; VEGFR; Angiogenesis; Metastatic colorectal cancer
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation
Keywords: Nintedanib; BIBF 1120; Ovarian cancer; Angiogenesis; VEGF; BRCA